Icatibant Glenmark

Icatibant, the active ingredient in Icatibant Glenmark, is a bradykinin B2 receptor antagonist presented as a subcutaneous formulation for injection use. It is indicated for the treatment of acute attacks of hereditary angioedema in patients with C1‑inhibitor deficiency. GNH USA supplies Icatibant Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant acts on the bradykinin pathway to relieve swelling in hereditary angioedema. - Acute hereditary angioedema (C1‑inhibitor deficiency): rapidly reduces edema and restores airway patency during an attack.

Icatibant may cause a range of adverse reactions, most of which are related to the injection site or systemic exposure.

Common Side Effects: - Injection site pain: discomfort at the site of subcutaneous administration. - Redness or erythema: localized skin reddening. - Swelling at injection site: mild to moderate edema. - Headache: transient cranial discomfort. - Nausea: occasional gastrointestinal upset.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Angioedema of the face or throat: worsening swelling despite therapy. - Hypotension: significant drop in blood pressure. - Thrombocytopenia: reduced platelet count observed in rare cases. - Severe injection site necrosis: tissue death at the injection site.

Before using Icatibant, consider the following safety measures. - Pregnancy: safety has not been established; use only if clearly needed. - Breastfeeding: unknown whether the drug is excreted in milk; weigh benefits against risks. - Renal impairment: monitor renal function and adjust therapy if necessary. - Concomitant ACE inhibitors or neprilysin inhibitors: increased bradykinin levels may heighten risk of angioedema. - Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other agents that affect bradykinin or vascular tone.

Major Interactions (Avoid): - ACE inhibitors: may amplify bradykinin‑mediated angioedema. - Neprilysin inhibitors: increase bradykinin levels, raising risk of severe swelling.

Moderate Interactions (Monitor Closely): - Angiotensin II receptor blockers (ARBs): observe for enhanced hypotensive effects. - Estrogen‑containing oral contraceptives: may modestly increase angioedema risk. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): monitor for additive vasodilatory effects.